Risk prognosis correlation of Insulin-like growth factor binding protein-3 and insulin-like growth factor-1 uterine fibroids
IGFBP-3 and IGF-1 in uterine fibroids
Abstract
Objective: To explore the relationships between the levels of serum insulin-like growth factor binding protein-3 (IGFBP-3) and insulin-like growth factor 1 (IGF-1) and immune factors as well as the prognosis of patients with uterine fibroids.
Methods: The study group consisted of 186 patients with uterine fibroids who had laparoscopic myomectomy between June 2023 and June 2024, whereas the control group consisted of 208 healthy women who had physical tests over the same time period. The patients in the study group were divided into a good prognosis group (84 patients) and a poor prognosis group (92 patients). The levels of GFBP-3, IGF-1 and immune factors in the study group and the control group, and their relationships with prognosis were analyzed.
Results: There were ten patients who left the study group and eight who left the control group. IGFBP-3 and IGF-1 in the study group were (303.18±42.39) mg/L and (1377.11±84.78) mg/L, which both outperformed those in the control contingent [(231.25±34.18) mg/L and (438.09±52.15) mg/L] (t=12.87, 19.63) P < 0.001). Whereas the levels of CD 3+, CD 4+, and CD 4+/CD 8+ were lower than those in the control group (t=7.92, 8.41, 5.21, P < 0.001). Both values were higher [(284.63±36.19) mg/L and (434.91±53.28) mg/L]. P < 0.001 (t=5.96, 64.19). While the numbers of CD 3+, CD 4+, and CD 4+/CD 8+ cells were lower than those in the good prognosis group (t=5.31, 7.03, 3.15). There was a positive correlation between CD 8+ status and IGFBP-3, history of uterine fibroids, number of fibroids, history of miscarriage, and duration of breastfeeding (r=0.593, 0.452, 0.446, 0.419, 0.422, respectively). IGF-1 was negatively correlated with CD 3+, CD 4+, and CD 4+/CD 8+ (r=-0.720, -0.751, and -0.712, respectively). IGF-1 was positively correlated with CD 8+ status, history of uterine fibroids, number of fibroids, history of miscarriage, and duration of breastfeeding (r=0.631, 0.503, 0.444, 0.501, 0.451). Number of fibroids, a history of miscarriage, and the length of breastfeeding were risk variables that impacted uterine fibroids patients' prognosis.
Conclusion: The levels of IGFBP-3, IGF-1 and CD-8+ in patients with uterine fibroids are relatively high. Moreover, IGFBP-3 and IGF-1 are related to immune factors and patient prognosis.
References
2.Zanolli NC, Bishop KC, Kuller JA, Price TM, Harris BS. Fibroids and Fertility: A Comparison of Myomectomy and Uterine Artery Embolization on Fertility and Reproductive Outcomes. Obstet Gynecol Surv. 2022 Aug;77(8):485-494. doi: 10.1097/OGX.0000000000001052. PMID: 35932289.
3.Sirkeci F, Moss J, Belli AM, McPherson K, Daniels J, Manyonda I, Middleton L, Cheed V, Wu O, Lumsden MA; FEMME Trial Collaborative Group. Effects on heavy menstrual bleeding and pregnancy of uterine artery embolization (UAE) or myomectomy for women with uterine fibroids wishing to avoid hysterectomy: The FEMME randomized controlled trial. Int J Gynecol Obstet. 2023 Feb;160(2):492-501. doi: 10.1002/ijgo.14626. PMID: 36511801; PMCID: PMC10107788.
4.Peng J, Wang J, Shu Q, Luo Y, Wang S, Liu Z. Systematic review and meta-analysis of current evidence in uterine artery embolization vs myomectomy for symptomatic uterine fibroids. Sci Rep. 2024 Aug 20;14(1):19252. doi: 10.1038/s41598-024-69754-0. PMID: 39164326; PMCID: PMC11336172.
5.Bao YM, Ma WW, Li S, Jiang L, Yang MJ, Chen JY. The safety and efficacy of myomectomy in the treatment of recurrent uterine fibroids after HIFU. Int J Gynecol Obstet. 2024 Dec;167(3):997-1003. doi: 10.1002/ijgo.15757. Epub 2024 Jun 27. PMID: 38935313.
6.Yu S, Bhagavath B, Shobeiri SA, Eisenstein D, Levy B. Clinical and Patient Reported Outcomes of Pre- and Postsurgical Treatment of Symptomatic Uterine Leiomyomas: A 12-Month Follow-up Review of TRUST, a Surgical Randomized Clinical Trial Comparing Laparoscopic Radiofrequency Ablation and Myomectomy. J Minim Invasive Gynecol. 2022 Jun;29(6):726-737. doi: 10.1016/j.jmig.2022.01.009. Epub 2022 Jan 24. PMID: 35085837.
7.Anchan RM, Spies JB, Zhang S, Wojdyla D, Bortoletto P, Terry K, Disler E, Milne A, Gargiulo A, Petrozza J, Brook O, Srouji S, Morton CC, Greenberg J, Wegienka G, Stewart EA, Nicholson WK, Thomas L, Venable S, Laughlin-Tommaso S, Diamond MP, Maxwell GL, Marsh EE, Myers ER, Vines AI, Wise LA, Wallace K, Jacoby VL. Long-term health-related quality of life and symptom severity following hysterectomy, myomectomy, or uterine artery embolization for the treatment of symptomatic uterine fibroids. Am J Obstet Gynecol. 2023 Sep;229(3):275.e1-275.e17. doi: 10.1016/j.ajog.2023.05.020. Epub 2023 May 26. PMID: 37244458.
8.Tsiampa E, Tsiampas K, Kapogiannis F. Perioperative and reproductive outcomes' comparison of mini-laparotomy and laparoscopic myomectomy in the management of uterine leiomyomas: a systematic review. Arch Gynecol Obstet. 2024 Mar;309(3):821-829. doi: 10.1007/s00404-023-07168-5. Epub 2023 Aug 11. PMID: 37566224.
9.Deipolyi AR, Annie F, Bush SH 2nd, Spies J. Hysterectomy and Myomectomy versus Uterine Artery Embolization for Symptomatic Fibroids and Adenomyosis: National and Regional Trends and Adverse Events in 70,000 Patients. J Vasc Interv Radiol. 2025 Jun;36(6):1011-1018.e4. doi: 10.1016/j.jvir.2025.02.026. Epub 2025 Feb 28. PMID: 40024281.
10.Chen Y, Yi J, Lin S, Xie X, Liu X, Guo SW. Reproductive outcomes of high-intensity focused ultrasound ablation and myomectomy for uterine fibroids: a systematic review and meta-analysis. Reprod Biomed Online. 2025 Jan;50(1):104436. doi: 10.1016/j.rbmo.2024.104436. Epub 2024 Sep 3. PMID: 39616958.
11.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852. doi: 10.18632/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137.
12.Tanigawa T, Omatsu K, Aoki Y, Fusegi A, Omi M, Netsu S, Okamoto S, Yunokawa M, Nomura H, Kanao H. Impact on prognosis of unexpected uterine sarcoma with scalpel morcellation or enucleation. Gynecol Oncol Rep. 2022 Sep 15;43:101070. doi: 10.1016/j.gore.2022.101070. PMID: 36164469; PMCID: PMC9508150.
13.Fajardo OM, Grebenyuk E, Chaves KF, Zhao Z, Ding T, Curlin HL, Harvey LFB. Impact of trainees involvement on surgical outcomes of abdominal and laparoscopic myomectomy. J Obstet Gynecol. 2024 Dec;44(1):2330697. doi: 10.1080/01443615.2024.2330697. Epub 2024 Mar 23. PMID: 38520272.
14.Yang ZM, Malka R, Erwin DZ, Postma G. Airway and Voice Outcomes After Thyroarytenoid Myomectomy for Bilateral Vocal Fold Immobility. Laryngoscope. 2024 Oct;134(10):4307-4312. doi: 10.1002/lary.31545. Epub 2024 May 28. PMID: 38807469.
15.Mahalingam M, Hu M, Schointuch M, Szychowski JM, Harper L, Owen J, Sinkey R. Uterine myomas: effect of prior myomectomy on pregnancy outcomes. J Matern Fetal Neonatal Med. 2022 Dec;35(25):8492-8497. doi: 10.1080/14767058.2021.1984424. Epub 2021 Oct 6. PMID: 34615420; PMCID: PMC10961099.
16.Thao V, Moriarty JP, Stewart EA, Borah BJ. Cost-effectiveness of Myomectomy versus Hysterectomy in Women with Uterine Fibroids. J Minim Invasive Gynecol. 2023 Oct;30(10):813-819. doi: 10.1016/j.jmig.2023.06.001. Epub 2023 Jun 5. PMID: 37286130.
17.Yu WN, Pan SY, Wang C, Huang ZD, Wang XL, Zhu S, Ding Y, Wang XL. [Clinicopathological features and prognosis of 117 cases of fumarate hydratase-deficient uterine leiomyomas]. Zhonghua Fu Chan Ke Za Zhi. 2025 Jun 25;60(6):450-460. Chinese. doi: 10.3760/cma.j.cn112141-20250205-00040. PMID: 40582968.
18.Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines. 2022 Sep 10;10(9):2248. doi: 10.3390/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572.
19.Allen A, Schembri M, Parvataneni R, Waetjen LE, Varon S, Salamat-Saberi N, Tassone S, Williams N, Kho KA, Jacoby VL. Pregnancy Outcomes After Laparoscopic Radiofrequency Ablation of Uterine Leiomyomas Compared With Myomectomy. Obstet Gynecol. 2024 May 1;143(5):612-618. doi: 10.1097/AOG.0000000000005548. Epub 2024 Mar 1. PMID: 38422502.
20.Kinariwala DJ, Khaja MS, McCann S, Sheeran D, Park AW, Wilkins LR, Matsumoto AH, Redick DL. Preoperative uterine artery embolization before hysterectomy or myomectomy: a single-center review of 53 patients. Clin Imaging. 2023 Sep;101:121-125. doi: 10.1016/j.clinimag.2023.06.003. Epub 2023 Jun 9. PMID: 37329639.
21.Isono W, Maruyama M. A new uterine endometrium preservation hysteroscopic myomectomy: Introduction of improved procedures and a retrospective analysis of 94 cases. Eur J Obstet Gynecol Reprod Biol X. 2024 Nov 14;24:100354. doi: 10.1016/j.eurox.2024.100354. PMID: 39639964; PMCID: PMC11617695.
22.Kitade M, Kumakiri J, Kobori H, Murakami K. The effectiveness of relugolix compared with leuprorelin for preoperative therapy before laparoscopic myomectomy in premenopausal women, diagnosed with uterine fibroids: protocol for a randomized controlled study (MyLacR study). Trials. 2024 May 24;25(1):343. doi: 10.1186/s13063-024-08170-1. PMID: 38790029; PMCID: PMC11127340.
23.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861. doi: 10.3390/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220.
24.Wang P, Di Francesco L, Seeraj V, Kumari S, Moustafa S, Uzianbaeva L, Mehdizadeh A. Minimally Invasive Myomectomy with Temporary Bilateral Uterine Artery Blockage at Anterior Cul-de-Sac. JSLS. 2025 Jan-Mar;29(1):e2024.00078. doi: 10.4293/JSLS.2024.00078. Epub 2025 Mar 25. PMID: 40144384; PMCID: PMC11935644.
25.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603. doi: 10.1097/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349.
26.Sinha R, Bana R, Peddappolla SC. Feasibility and surgical outcomes of robotic myomectomy for large and multiple uterine fibroids- insights from a decade of experience at a single center. J Robot Surg. 2025 Jul 11;19(1):377. doi: 10.1007/s11701-025-02538-4. PMID: 40646378; PMCID: PMC12254167.
27.Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs. 2022 Oct 1;33(9):943-959. doi: 10.1097/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295.
28.Sandrieser L, Kuessel L, Perricos A, Wenzl R, Husslein H. Myomectomy for a large uterine fibroid via mini-laparotomy: a step-by-step video tutorial. Fertil Steril. 2022 Feb;117(2):456-457. doi: 10.1016/j.fertnstert.2021.11.018. Epub 2021 Dec 31. PMID: 34980426.
29.Amoah A, Quinn SD. Uterine-preserving treatments or hysterectomy reintervention after myomectomy or uterine artery embolisation: A retrospective cohort study of long-term outcomes. BJOG. 2023 Jun;130(7):823-831. doi: 10.1111/1471-0528.17412. Epub 2023 Feb 15. PMID: 36706789.
30.Anchan RM, Wojdyla D, Bortoletto P, Terry K, Disler E, Milne A, Gargiulo A, Petrozza J, Brook O, Srouji S, Morton CC, Greenberg J, Wegienka G, Stewart EA, Nicholson WK, Thomas L, Venable S, Laughlin-Tommaso S, Diamond MP, Maxwell GL, Marsh EE, Myers ER, Vines AI, Wise LA, Wallace K, Jacoby VL, Spies JB. A Comparative Analysis of Health-Related Quality of Life 1 Year Following Myomectomy or Uterine Artery Embolization: Findings from the COMPARE-UF Registry. J Womens Health (Larchmt). 2023 Apr;32(4):423-433. doi: 10.1089/jwh.2022.0133. Epub 2023 Jan 13. PMID: 36637808; PMCID: PMC10079244.
31.Zhou Y, Lin Y, Xu D, He L, Huang L. A comparative study of prone split-leg position and lithotomy position in posterior uterine myomectomy by transvaginal natural orifice transluminal endoscopic surgery. BMC Womens Health. 2025 Apr 12;25(1):177. doi: 10.1186/s12905-025-03709-z. PMID: 40221707; PMCID: PMC11994009.
Copyright (c) 2025 Tingting Lin, Keke Qian, Yanping Chen, Mengshu Li, Zhang Zhang
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.